EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study

Zishuo Wang, Xiaodong Xu, Pengwei Lv, Jianxiang Zhang

Frontiers in Oncology · 12.05.2026 · 16

DOI: 10.3389/fonc.2026.1795498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 12.05.2026. Verfasst von Zishuo Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Eribulin is a microtubule inhibitor indicated for metastatic breast cancer (MBC). Previous studies have demonstrated its overall survival benefit in patients with MBC, but data on its efficacy in those with liver metastases are lacking.

Methods

We retrospectively analyzed the efficacy and safety of eribulin in 73 patients with liver metastases from breast cancer treated at the First Affiliated Hospital of Zhengzhou University between 2020 and 2024. Systemic progression-free survival and objective response rate were assessed per RECIST version 1.1, and adverse events were evaluated.

Results

The median progression-free survival was 3.7 months (95% CI: 2.8–4.6), with a systemic objective response rate of 15.1% (95% CI: 7.8%–25.4%; partial responses only). The highest objective response rate (21.2%) was numerically observed in the HR+/HER2− subtype. The most common adverse events were neutropenia (42.5%), fatigue (37.0%), alopecia (34.2%), and peripheral neuropathy (28.8%), with no treatment-related deaths.

Conclusions

In this single-center retrospective exploratory analysis, eribulin-based therapy demonstrated preliminary activity in heavily pre-treated breast cancer patients with liver metastases. These hypothesis-generating findings warrant further prospective validation.

Schlagwörter

Stichwörter der Autor:innen

breast cancereribulinliver metastasesmetastatic breast cancerobjective response rateprogression-free survivalreal-world studyretrospective study

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Zitieren

APA

Wang, Z., Xu, X., Lv, P., & Zhang, J. (2026). Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1795498

Vancouver

Wang Z, Xu X, Lv P, Zhang J. Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1795498

BibTeX
@article{Wang2026,
  author = {Wang, Zishuo and Xu, Xiaodong and Lv, Pengwei and Zhang, Jianxiang},
  title = {Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1795498}
}
Kostenlos starten →